Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isunakinra in Moderate to Severe Allergic Conjunctivitis
NCT02492321Phase 3Completed
- Sponsor
- Sesen Bio
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing EBI-005 with Vehicle (2 arms). Primary endpoint: Morning ocular itching diary scores at 14 days. Started Jul 2015; status: completed.
02
Drugs
isunakinra
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02492321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492321.